Cellevate AB Secures $3.2M in Seed Round Funding to Revolutionize Bioprocessing Technology

We are thrilled to announce that Cellevate AB has successfully raised $3.2 million in its latest funding round, a significant investment that underscores our commitment to pioneering advancements in the field of bioprocessing. At Cellevate, we specialize in developing and marketing innovative products based on our proprietary nanofiber-based platform, Cellevat3d™. This unique technology has the potential to revolutionize upstream bioprocessing, bridging the gap from research and development to commercial manufacturing, and ultimately enhancing the capabilities of next-generation cell- and gene therapies. The funding will primarily support the launch of our newest product line, the Cellevat3d™ carriers, which are set to hit the market in 2024. These state-of-the-art carriers create extracellular-like environments, providing exceptional surface areas for adherent cell cultures. Early results from our research indicate that this innovative solution could substantially increase yields while minimizing risks and lowering costs throughout the development and manufacturing processes. As we move forward, this investment allows Cellevate to accelerate our R&D efforts, expand our team, and amplify our marketing initiatives, ensuring that we are prepared for a successful product launch in the upcoming year. We are excited about the impact our technology will have on the biopharmaceutical industry, and we look forward to contributing to breakthroughs that improve patient outcomes. For more information on our pioneering products and vision, please visit us at www.cellevate.com.